Risultati per: Prima terapia farmacologica per l’apnea notturna (OSAS)

Stroke, Volume 56, Issue Suppl_1, Page AWP266-AWP266, February 1, 2025. Background:Sleep apnea symptoms, such as snoring and breathing pauses, often co-occur with depression in stroke survivors, adversely affecting recovery and quality of life. This study examines the relationship between the frequency of these symptoms and depression in stroke survivors.Methods:Data were analyzed from 737 stroke survivors enrolled in the Stroke Transitions Education and Prevention (STEP) clinic from January 2021 to August 2023. Sleep apnea symptoms were assessed using a modified questionnaire that emphasized frequent symptoms such as snoring, breathing pauses, being severely overweight, morning headaches, dry mouth, and gasping arousals. The presence of these symptoms contributed to coding participants as “Yes” for sleep apnea. Data were collected from patients seen over telemedicine or through electronic form submissions. Patients who opted out of participation in the registry were excluded from the analysis. Depression was measured using the Patient Health Questionnaire-9 (PHQ-9) and coded as binary: “Yes” for a PHQ-9 score ≥5 (mild to severe depression) and “No” for a score

90% di quelli estremamente pretermine sottoposto a cure dolorose

Test avviati negli Usa. A Ferrara trattata una paziente, tra i primi centri in Europa

Parte dall’Abruzzo ‘Respirare è un diritto di tutti’

L’opposizione critica sul mancato incarico al vicepresidente

Stabilizza vista e può ridurre necessità iniezioni intravitreali

Da biopsia liquida a studio cellule epatiche, per malattie rare

Efficace nel 30% dei pazienti che non risponde alle altre cure

Mouth taping is a sleep technique that has been promoted widely across social media. Although mouth breathing during sleep is associated with severity of obstructive sleep apnea (OSA), research recently published in JAMA Otolaryngology–Head & Neck Surgery suggests that it may be important to maintain airflow in some patients with nasal obstruction.

Circulation, Volume 150, Issue Suppl_1, Page A4136996-A4136996, November 12, 2024. Introduction:Insomnia and obstructive sleep apnea (OSA) each increase risk for hypertension (HTN). Among older adults, there is a negative synergistic association of comorbid insomnia and OSA (i.e., COMISA) on incident cardiovascular disease (CVD) but it is unknown if this comorbidity is associated with HTN risk earlier in the lifespan.Research Questions:1) Is COMISA associated with incident HTN among younger adults? 2) Do COMISA-HTN associations differ by sex?Hypotheses:We hypothesized that 1) COMISA would be associated with a greater risk of HTN than having no sleep disorder, 2) the hazard would be larger than for insomnia and OSA alone, and 3) distinct COMISA-HTN associations would be observed among men and women, respectively.Methods:Analyses included Veterans who enrolled in Veterans Health Administration (VA) care 2001-2021, a group selected because of its early adult age distribution. We merged administrative data, including outpatient and inpatient encounters, diagnoses, (ICD-9-CM/10 codes/dates) and pharmacy records. Veterans without demographic data, a history of other sleep disorders or CVD, or

Circulation, Volume 150, Issue Suppl_1, Page A4140180-A4140180, November 12, 2024. Introduction:Sleep apnea is a common sleep disorder that can worsen atrial fibrillation(AF) prognosis. Benzodiazepines(BZD) are commonly prescribed for insomnia, which often accompanies sleep apnea. However, BZDs have been associated with worsening of sleep apnea due to respiratory depression, pharyngeal muscle relaxation, and increase of arousal threshold, which all may lead to prolonged hypoxia. There is little research on the effect of BZD use in AF patients with sleep apnea. Therefore, the objective of this study is to investigate the effects of BZD usage on outcomes in the AF population with sleep apnea.Methods:Data from patients with AF and sleep apnea seen at Tulane Medical Center between 2010 and 2019 was obtained from Research Action for Health Network(REACHnet), a Clinical Research Network in PCORnet®. Patients with AF and sleep apnea were divided between those with a prescription of BZD and those without BZD. These two groups were compared using the Kaplan-Meier method for time-to outcome for all-cause mortality, ischemic stroke, myocardial infarction(MI), and hospitalizations in the five years following their AF diagnosis. Cox regression analysis was used to investigate proportional hazards and control for demographics, comorbidities, and medication use.Results:There were 524 total patients included with AF and sleep apnea. Of these, 413(78.8%) were not prescribed BZDs, while 111(21.1%) were taking BZDs. Use of BZDs was associated with worse outcomes. In the no BZD and the BZD group over the 5 years following AF diagnosis, the rate of mortality was 6.1% and 12.6%(p

Circulation, Volume 150, Issue Suppl_1, Page A4136963-A4136963, November 12, 2024. Background:There is increasing evidence of a strong association between obstructive sleep apnea (OSA) and ischemic heart disease. Previous studies have demonstrated OSA to be a significant predictor of incident CAD, while recent studies have confirmed individuals with OSA to have 3.9 times greater incidence of major adverse cardiac and cerebrovascular events (MACCE) at one year following acute myocardial infarction (AMI) than individuals without OSA. Whether treatment with continuous positive airway pressure (CPAP) after AMI in OSA patients reduces MACCE is not known. This study investigated the long-term cardiovascular outcomes associated with CPAP therapy after AMI in OSA patients, and is the first study to evaluate the effect of CPAP on secondary prevention after AMI.Methods:This retrospective study was conducted from 2015 to 2019 and included adults with AMI. Patients with at least moderate OSA (n=180) were followed for at least 1 year and categorized as either AMI and compliant to CPAP (54 patients) or AMI and non-compliant to CPAP (126 patients). We estimated the incidence of MACCE (early rehospitalization, re-catheterization, CABG, recurrent MI, CHF, arrhythmia, stroke, and death) in each group during follow-up from the index event. Continuous and categorical variables were analyzed for significance with Wilcoxon’s test and Fisher’s exact test respectively. Multivariate analyses were performed to adjust for confounders.Results:Most participants were male, the average age was 66 years old, and no significant demographic difference was identified between the two groups. Compared with non-compliant patients, CPAP-compliant patients exhibited significantly lower overall MACCE incidence (22.2% vs 40.5%, p=0.03) and repeat catheterization rate (1.9% vs 11.1%, p=0.04) after AMI.Conclusion:Long-term, compliant CPAP therapy, as compared with non-compliant CPAP therapy, significantly reduces recurrent cardiovascular events and provides effective secondary prevention after AMI in patients with at least moderate OSA.